天士力(600535.SH):子公司就STRO-002相關權益與Sutro簽署許可協議
格隆匯12月24日丨天士力(600535.SH)公佈,公司控股子公司天士力生物醫藥股份有限公司(“天士力生物”)獲得美國Sutro Biopharma,Inc.(簡稱“Sutro”)的獨家許可,在區域內(即中國大陸、香港及澳門特別行政區、台灣地區,下同)獨家開發和商業化一種靶向葉酸受體α(FRα)的抗體偶聯藥物(簡稱“STRO-002”),STRO-002目前在歐美進行鍼對卵巢癌和子宮內膜癌的臨牀研究。天士力生物將向Sutro支付4000萬美元首付款和潛在最高3.45億美元的開發及商業化里程碑付款,以及約定比例的銷售提成。
根據《許可協議》約定,天士力生物將獲得STRO-002在區域內的針對卵巢癌、非小細胞肺癌、三陰性乳腺癌以及其他適應症獨家開發和商業化權益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.